Kornimate/medical-research-clean huggingface dataset:
chlamydia trachomatis persistence in the female gastrointestinal tract

Conditions: Chlamydia Infection

Summary: the purpose of this study is to determine if chlamydial infections persist in the rectum of females who have had a sexually transmitted infection of chlamydia.


Eligibility criteria:
inclusion criteria: * 11-19 years old * female * diagnosis of chlamydia on enrollment visit * invitation to participate control group exclusion criteria: * age out of range * negative chlamydia screen (unless qualifies for control group) * unable to provide needed samples

Keywords: adolescent health sexually transmitted infection women's health
observatory of immunological thrombopenic purpura in the brest region

Conditions: Immune Thrombocytopenia

Summary: database of patients with itp, diagnosed, treated and followed in the brest university hospital.

creation of a global clinical and biological database for all patients diagnosed, treated and followed for itp in the university hospital of brest. uhb is the regional reference center (competence center) on hemorrhagic diseases. dr pan-petesch, who is responsible of the local competence center, is affiliated to the national sector of auto-immune cytopenias cerecai-marih).

Eligibility criteria:
inclusion criteria: * patients with itp agree to participate exclusion criteria: * other thrombocythopenia other than itp * patients under guardianship * patients without national social security
perioperative cardiac troponin levels in healthy adults

Conditions: Extremity Orthopedic Surgery

Summary: this study will determine the extent of high-sensitivity cardiac troponin (hs-ctn) release in patients without cardiac risk factors undergoing extremity orthopedic surgery. this study will provide important evidence on how to interpret postoperative cardiac troponin elevations.


Eligibility criteria:
inclusion criteria: * age 18-35 years * extremity orthopedic or trauma surgery: leg, hip, arm, shoulder. * planned overnight hospital admission * no cardiac risk factors (lee's revised cardiac risk index class 1) * american society of anesthesiologists (asa) physical status i-ii exclusion criteria: * any history or symptoms of cardiac disease * kidney or liver disease * recent or current trauma to the trunk or head * persons with increased vulnerability (e.g. cognitive limitations, prisoners,...) * pregnancy

Keywords: cardiac troponin perioperative period surgery
activity level monitoring study

Conditions: Obesity; Morbid Obesity

Summary: the purpose of this study is to 1) evaluate the relationship of physical activity to quality of life and psychological functioning among adults with severe obesity (bmi\>40) and 2) evaluate the effects of activity monitoring on changes in physical activity during a 6-week intervention interval.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * bmi greater than or equal to 40 * sit or lie down greater than or equal to 9 hours per day exclusion criteria: * participating in regular exercise (any planned exercise) * participating in a formal weight loss or exercise program * planning to join a formal weight loss or exercise program in the next 2 months * cannot stand up without assistance * currently pregnant * planning to get pregnant in the next 2 months * given birth in past 9 months * currently breast feeding * weigh over 400 lbs * highest level of education is below 8th grade * phq-9 score less than 15 * visual impairment that impairs ability to read * any condition(s) that would make it challenging to follow instructions/directions * cognitive disorder (e.g., dementia)

Keywords: sedentary activity morbid obesity obesity actigraph
alzheimer's caregiver communication study

Conditions: Alzheimer's Disease

Summary: the point of this research is to improve the communicative relationship between the caregiver and care receiver. it is input from the caregiver on these communicative behaviors that will inform the process of understanding how to reduce the caregiver burden that comes from this communicative relationship.

this research study is developing a new checklist to measure communicative coping behaviors of persons with alzheimer's disease in the home environment. the communicative coping behavior checklist (ccbc) is an observation checklist to be completed by the caregiver or knowledgeable informant. the current version includes 23 behaviors to be rated for frequency and effectiveness. the behaviors that will be observed cover management of memory loss within three broad categories: humor, explanations, and general coping behaviors. two kinds of couples will participate in this study. one includes a person with alzheimer's disease and their caregiver. the second includes a cognitively intact participant and study partner, both over the age of 60, to serve as controls. study visit 1 (3 hours long) during the first visit, the person with alzheimer's disease/control participant can expect to be asked questions about their memory, thinking and concentration, demographics, quality of life, and mood. the caregiver/study partner will be asked about their quality of life, mood, and daily activities. at the end of the visit the caregiver/study partner will be given a copy of the ccbc and asked to take it home. s/he will be instructed to rate the person with alzheimer's disease/ control participant's communicative coping behavior over the course of the next two weeks. at the end of that time, a research assistant will call the caregiver/study partner and administer the ccbc over the telephone. study visit 2 (3 hours long) the second visit will occur in the clinic approximately 12 months from the date of the first visit. as with the first study visit, again both the person with alzheimer's disease/control participant and the caregiver/study partner will answer questions about their memory, quality of life, mood, and daily activities. once again, the caregiver/study partner will be given a copy of the ccbc and asked to take it home and complete. both visits will take about three hours for the caregiver/study partner and about two hours for the person with dementia or control subject.

Eligibility criteria:
\*note\* currently enrolling participants for control group only inclusion criteria: * couples including spouse or family member who spend at least 2-3 hours per day together * both must be cognitively intact exclusion criteria: * cognitive impairment

Keywords: communication behavior coping functional ability quality of life caregiving
megestrol acetate plus lng-ius in young women with endometrial atypical hyperplasia

Conditions: Atypical Endometrial Hyperplasia

Summary: to see if megestrol acetate plus levonorgestrel-releasing intrauterine system (lng-ius) will not be inferior to returning the endometrial tissue to a normal state than megestrol acetate or lng-ius alone in patients with endometrial atypical hyperplasia.

after diagnosed of endometrial atypical hyperplasia (eah) by hysteroscopy, patients will be enrolled. age, waist circumstances, blood pressure, basic history of infertility, blood pressure, serum lipid level and side effects will be collected. blood tests, including fasting blood glucose (fbg), postprandial blood glucose (pbg), fasting insulin (fins), shbg, sex hormone levels, blood lipids and anti-müllerian hormone(amh) will be performed before treatment to evacuate their metabolic conditions. patients are randomized to 1 of 3 treatment groups. patients will receive ma (megestrol acetate) 160 mg by mouth daily for at least 3 months on arm i. patients will receive lng-ius insertion on arm ii and ma 160 mg plus lng-ius insertion on arm iii. then an hysteroscope will be used to evaluate the endometrial condition every 3 months, and the findings will be recorded. for patients with eah, complete response (cr) is defined as the reversion of endometrial atypical hyperplasia to proliferative or secretory endometrium; partial response (pr) is defined as regression to simple or complex hyperplasia without atypia; no response (nr) is defined as the persistence of the disease; and progressive disease (pd) is defined as the appearance of endometrial cancer in patients. continuous therapies will be needed in pr, nr or pd. after completion of study treatment, 2 months of maintenance treatment will be recommended for patients with cr, and participants will be followed up for 2 years.

Eligibility criteria:
inclusion criteria: * primarily have a confirmed diagnosis of endometrial atypical hyperplasia based upon hysteroscopy * have a desire for remaining reproductive function or uterus * need to be able to undergo correlative treatment and follow-up exclusion criteria: * acute liver disease or liver tumor (benign or malignant) or renal dysfunction * pregnancy or suspicion of pregnancy * have a history of eah and have disease relapse during merina insertion * under treatment of high-dose progestin therapy more than 3 months in recent 6 months * congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity * confirmed diagnosis of malignant tumor in genital system * acute severe disease such as stroke or heart infarction or a history of thrombosis disease * hypersensitivity or contradiction to any component of this product * ask for removal of the uterus or other conservative treatment * smoker(\>15 cigarettes a day)

Keywords: levonorgestrel-releasing intrauterine system megestrol acetate atypical endometrial hyperplasia
suicide intervention for alaska native youth

Conditions: Alaska Native Youth Aged 14 - 24; Suicide, Attempted; Suicidal Ideation; Alcohol Intoxication

Summary: two interventions will be delivered virtually to american indian/alaska native youth who have been hospitalized with suicidal attempt, suicidal ideation, or associated risk behaviors, including alcohol-related injury.

the investigators will conduct a randomized controlled trial whereby alaska native (an) youth who are hospitalized for suicide risk will be randomly assigned to either qungasvik/tools for life or tools for life + motivational interviewing social network (misn) intervention after their baseline survey, and followed up at 3-, 6-, and 12 months. all youth will receive tools for life and two 30-minute virtual follow-up visits (at 2- and 6-weeks post intervention) focused on connectivity to culture and obtaining support from intergenerational social networks in their home communities. half of the youth will also receive misn in addition to tools for life. both interventions will be delivered virtually by a wellness team comprised of alaska native community behavioral health aides, prevention specialists and/or elders who function in their communities as natural healers.

Eligibility criteria:
inclusion criteria: * self-identify as alaska native youth * between the ages of 14 and 24 * admitted to the hospital for suicide attempt, ideation, or associated risk behaviors including alcohol-related injury or acute intoxication exclusion criteria: -

Keywords: alaska native youth, suicide, prevention, culture
effect of 2.5 years of rasagiline therapy on progression of cognitive biomarkers assessed by mri in parkinson's disease.

Conditions: Parkinson's Disease

Summary: in this investigator-initiated study, we will compare changes in brain cognitive biomarkers assessed by diffusion tensor imaging over 2.5 years among 12 patients with idiopathic parkinson's disease (ipd) receiving rasagiline, 20 ipd patients not receiving mao-b inhibitors and 25 age-matched healthy controls. will also compare the changes in mini-mental state exam (mmse) and montreal cognitive assessment (moca) scores and plasma brain-derived neurotrophic factor (bdnf) with changes in brain cognitive biomarkers in all ipd patients and hc over 2.5 years.


Eligibility criteria:
ipd or hc subjects who were enrolled in a similar study about 2.5 years ago and for whom baseline dti data are available.
study of rhopressa® for the reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension in a real-world setting

Conditions: Glaucoma, Open-Angle; Ocular Hypertension

Summary: to evaluate the iop lowering efficacy of netarsudil ophthalmic solution 0.02% when used as monotherapy or when used concomitantly with other iop-lowering agents in subjects with elevated iop due to open angle glaucoma or ocular hypertension in a real-world clinical setting. the study is an open-label design. the patients will receive treatment for 12 weeks.


Eligibility criteria:
key inclusion criteria: 1. male or female subjects (aged 18 or older) 2. subjects diagnosed with open-angle glaucoma or ocular hypertension, and determined by the treating physician to require additional intraocular pressure (iop)-lowering treatment with netarsudil 0.02%. 3. willingness to follow protocol requirements, including signed informed consent, routine follow-up schedule, completing questionnaires and completing laboratory tests key exclusion criteria: 1. have any active ocular disease other than glaucoma or ocular hypertension that would interfere with study interpretation 2. women of childbearing potential who are pregnant, nursing, or planning a pregnancy and not using a medically acceptable form of birth control. male subjects with a female partner of childbearing potential must have had a prior vasectomy or agree to use an effective method of birth control during the treatment period and for 3 months after the subject has completed the study. 3. known sensitivity or allergy to the study medication or components 4. any systemic disease or clinical evidence of any condition which would make the subject, in the opinion of the investigator, unsuitable for the study or could potentially confound the study results 5. concurrent participation or prior participation in any investigational drug or device study within the last 30 days prior to the baseline visit
a photodynamic therapy for treatment of actinic keratoses

Conditions: Actinic Keratoses

Summary: the purpose of this study is to compare the efficacy of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light vs absence of treatment for actinic keratoses.

this study seeks to evaluate the efficacy of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light vs. absence of treatment for actinic keratoses

Eligibility criteria:
inclusion criteria: age greater than or equal to 18 years * have a t least 4 nonhypertrophic ak lesions on the body * the subjects are in good health * the subject has the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate to the investigator exclusion criteria: * subjects who are pregnant or lactating * subjects with a history of cutaneous photosensitivity or porphyria, hypersensitivity to porphyrins, or photodermatosis * subjects with use of photosensitizing drugs within 1 week of study start * subjects with use of topical medications such as corticosteroids, alpha-hydroxyacids or retinoids 2 weeks before study entry * subjects with systemic steroid therapy within 4 weeks before study entry * subjects who received previous treatment of target aks * subjects with systemic treatment with chemotherapeutic agents, masoprocol (actinex), immunotherapy, or retinoids within 2 months of study entry * subjects with prior history of hypersensitivity reactions to lidocaine * subjects who are unable to understand the protocol or to give informed consent
non-invasive evaluation of fibrosis and steatosis in chronic hepatopathy

Conditions: Chronic Liver Disease; Steatohepatitis; Fibrosis

Summary: the purpose of this study is to evaluate non-invasive parameters for staging and grading of chronic hepatopathy in comparison to liver biopsy.

for diagnosis, staging and grading of chronic liver disease, liver biopsy is the gold standard to date. unfortunately, being an invasive diagnostic method, liver biopsy has a significant morbidity. furthermore, due to the small sample size, sampling error (over- or underestimating severity of liver disease) is a serious problem in diagnostic of chronic liver disease. the objective of this study is to evaluate non-invasive diagnostic methods (mri, elastography, ultrasound and serum parameters) in comparison to the gold standard to establish criteria for diagnostic in liver disease and reduce the necessary amount of liver biopsies in the future and allow regular follow up.

Eligibility criteria:
inclusion criteria: * chronic hepatopathy and necessity of liver biopsy exclusion criteria: * metal implants preventing mri

Keywords: fibrosis steatosis liver biopsy elastography mri
effect of glp-1 receptor agonists on trabecular bone score

Conditions: Osteoporosis, Postmenopausal; Diabetes Mellitus, Type 2

Summary: this study will help determine the effect of glucagon like peptide-1 (glp-1)receptor agonists on bone strength in postmenopausal women with type 2 diabetes mellitus (t2dm)

postmenopausal women with diabetes mellitus have a higher risk of osteoporotic fractures, with significant associated mortality and morbidity. osteoporosis is underdiagnosed in diabetes, as the bone mineral density (bmd) as currently measured is often normal despite underlying abnormalities. the trabecular bone score (tbs) is a novel modality to assess bone microarchitecture and accurately assess fracture risk in patients with diabetes. due to increased co-prevalence of osteoporosis and diabetes mellitus, the potential effects of antidiabetic medications on fracture risk assume importance. based on findings in animal studies, we hypothesize that glp-1 receptor agonists increase tbs in postmenopausal women with (t2dm). the investigators propose a prospective non-randomized study by enrolling 48 patients (24 in the glp-1 group and 24 in the non-glp group). dual-energy x-ray absorptiometry (dxa )scans, markers of bone formation, and resorption, and selected inflammatory markers will be assessed at baseline, six months, and one year.

Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes mellitus * postmenopausal female * age \>55 years * hemoglobin a1c between 7-10% within 6 months of the first visit. exclusion criteria: * patients with type 1 diabetes mellitus * patients with a history of glp-1 receptor agonist/dpp4 inhibitor use * egfr \<30 ml/min in the last 3 months * patients with a history of pancreatitis * personal or family history of medullary thyroid cancer * patients with a history of treatment with anti-osteoporosis agents * documented secondary osteoporosis * documented presence of prosthesis or devices in the spine * unwilling or unable to consent
interdisciplinary intervention in patients with obesity and other metabolic diseases

Conditions: Obesity

Summary: the aim of the research study will be assess the effectiveness of a long-term interdisciplinary lifestyle in many aspects including food intake, psychological symptoms, physical activity habits, energy expenditure, body composition and anthropometric measurements in adults obese.

participants will be recruited after dissemination of the program in the local media and internet. they will go through a short interview to evaluate inclusion and exclusion criteria. thus, all obese adults will be submitted to an interdisciplinary lifestyle modification therapy according the inclusion criteria. the interdisciplinary therapy will consist of nutritional, physical exercise, psychological and physiotherapy support during the course of one year, according the literature the investigators promote a long term therapy to control obesity and metabolic diseases. the participants will be evaluated at baseline and after the therapy in accordance with ethical guidelines. the main purpose of this therapy is to enhance the quality of life of the participants promoting an active lifestyle and quality of life, adherence a healthy nutritional habits and a healthy weight loss. our focus will be on teaching strategies to maintain a healthy life style behaviors after therapy, our protocol is in agreement with public health field in this way.

Eligibility criteria:
inclusion criteria: * age from 30 to 50 years and body mass index (bmi) between 30 and 39.9 kg/m2 exclusion criteria: * musculoskeletal limitations preventing the practice of physical exercise, other metabolic or endocrine diseases, identified genetic diseases, pregnancy, previous drug utilization and excessive chronic alcohol consumption

Keywords: obesity metabolic syndrome x interdisciplinary studies
cadonilimab combined with chemotherapy as first or second line treatment in recurrent or metastatic triple negative breast cancer

Conditions: Triple-negative Breast Cancer; Cadonilimab

Summary: the prognosis of recurrent and metastatic triple negative breast cancer (tnbc) is poor, and chemotherapy is still the main treatment for tnbc. some studies have shown that combination therapy of antibodies targeting cytotoxic t-lymphocyte antigen-4 (ctla-4) and programmed cell death-1 (pd-1) significantly improves clinical benefit over pd-1 antibody alone. however, broad application of this combination has been limited by toxicities. cadonilimab is a humanized immunoglobulin g1 bispecific antibody targeting pd-1 and ctla-4. it mutates to eliminate fc receptor and complement-mediated cytotoxic effects. the purpose of this study is to evaluate the efficacy and safety of cadonilimab combined with chemotherapy as a first or second-line treatment of recurrent and metastatic tnbc. this study is a multicenter, single arm, phase ii, non randomized, open label, simon two-stage design. it is planned to enroll 27 late stage tnbc patients.


Eligibility criteria:
inclusion criteria: * recurrent or metastatic tnbc patients; * tnbc defined by immunohistochemistry as er\<1%, pr\<1%, her2=0\~1+, or 2+ while her2 fish test shows no amplification； * previous received no or only first line chemotherapy treatment for recurrent or metastatic tnbc；when the time between cancer metastasis and the end of adjuvant chemotherapy exceeds 1 year, the systemic chemotherapy for metastasis treatment is recorded as first-line treatment; when less than 1year, the systemic chemotherapy for metastasis treatment is recorded as second-line treatment； * ages 18 to 75 years at the time of signing the informed consent form (icf); * eastern cooperative oncology group (ecog) performance status (ps) score of 0 or 1; * expected survival of ≥3 months; at least one measurable lesion per recist (version1.1); * acceptable renal and liver function; exclusion criteria: * they had received icis (i.e., anti-pd-1 antibodies, anti-pd-l1 antibodies, and anti-ctla-4 antibodies.)； * patients with active central nervous system (cns) metastatic lesions or meningeal metastases； * patients with an active autoimmune disease that requires systemic treatment in the past two years； * a known history of primary immunodeficiency； * pregnant or lactating women； * previous or current abnormalities of any disease, treatment, laboratory tests may confuse the study results, affect the subject's participation in the study

Keywords: triple negative breast cancer cadonilimab chemotherapy